Skip to main content
Top
Published in: Clinical Rheumatology 1/2009

01-01-2009 | Review Article

Pregnancy and rheumatic disease: “by the book” or “by the doc”

Authors: Stephanie O. Keeling, Anna E. Oswald

Published in: Clinical Rheumatology | Issue 1/2009

Login to get access

Abstract

Pregnancy is an important condition that can affect and be affected by rheumatic disease. Overall, pregnancy is viewed as a Th2-predominant state, but several Th1-related cytokines are vital to early pregnancy. In rheumatoid arthritis for example, the majority of women improve by the beginning of the second trimester, but the majority (90%) will flare in the first 3 to 4 months postpartum. In contrast, systemic lupus erythematosus has an unpredictable course in pregnancy, leaving most rheumatologists to recommend a disease-quiescent state prior to conception. Other diseases such as scleroderma are less clear because the disease less commonly presents in the childbearing period. Many immunosuppressive medications for the rheumatic diseases are contraindicated in pregnancy because of their mechanisms of action leaving only a select few “safe” medications. Significant heterogeneity between the Food and Drug Administration (FDA) category for a medication and what a rheumatologist does in clinic leads to confusion on how a patient should be treated for active rheumatic disease both peripartum and postpartum, particularly if the patient is breastfeeding. We review the general state of pregnancy and how it is affected by prototypical rheumatic diseases including rheumatoid arthritis and systemic lupus erythematosus. In addition, we present the most commonly used disease-modifying antirheumatic drugs and immunosuppressants and explain the difference between the FDA category and clinical practice among rheumatologists. Finally, we provide some general recommendations on how to manage a rheumatic disease during pregnancy including: (a) preconception planning to ensure no teratogenic medications on board, (b) early disclosure of pregnancy to all caregivers including the rheumatologist, family physician, obstetrician, and maternal–fetal medicine specialist, and (c) planning of safe medication use for acute flare-ups and disease suppression peripartum and postpartum.
Literature
1.
go back to reference Lockshin MD (2006) Treating rheumatic diseases in pregnancy: dos and don’ts. Ann Rheum Dis 65(Suppl III):iii58–iii60PubMedCrossRef Lockshin MD (2006) Treating rheumatic diseases in pregnancy: dos and don’ts. Ann Rheum Dis 65(Suppl III):iii58–iii60PubMedCrossRef
2.
go back to reference Ostensen M, Villiger PM (2007) The remission of rheumatoid arthritis during pregnancy. Semin Immunopathol 29:185–191PubMedCrossRef Ostensen M, Villiger PM (2007) The remission of rheumatoid arthritis during pregnancy. Semin Immunopathol 29:185–191PubMedCrossRef
3.
go back to reference Wegmann TG, Lin H, Guilbert L et al (1993) Bidirectional cytokine interactions in the maternal–fetal relationship: is successful pregnancy a Th2 phenomenon? Immunol Today 14:353–356PubMedCrossRef Wegmann TG, Lin H, Guilbert L et al (1993) Bidirectional cytokine interactions in the maternal–fetal relationship: is successful pregnancy a Th2 phenomenon? Immunol Today 14:353–356PubMedCrossRef
4.
go back to reference Ostensen M, Forger F, Villiger P (2006) Cytokines and pregnancy in rheumatic disease. Ann N Y Acad Sci 1069:353–363PubMedCrossRef Ostensen M, Forger F, Villiger P (2006) Cytokines and pregnancy in rheumatic disease. Ann N Y Acad Sci 1069:353–363PubMedCrossRef
5.
go back to reference Chaouat G, Ledee-Bataille N, Dubanchet S et al (2004) Th1/Th2 paradigm in pregnancy: paradigm lost? Int Arch Allergy Immunol 139:93–119CrossRef Chaouat G, Ledee-Bataille N, Dubanchet S et al (2004) Th1/Th2 paradigm in pregnancy: paradigm lost? Int Arch Allergy Immunol 139:93–119CrossRef
6.
go back to reference Ashkar AA, Di Santo JP, Croy BA (2000) Interferon gamma contributes to initiation of uterine vascular modification, decidual integrity, and uterine natural killer cell maturation during normal murine pregnancy. J Exp Med 192:25970CrossRef Ashkar AA, Di Santo JP, Croy BA (2000) Interferon gamma contributes to initiation of uterine vascular modification, decidual integrity, and uterine natural killer cell maturation during normal murine pregnancy. J Exp Med 192:25970CrossRef
7.
go back to reference Fukushima K, Miyamoto S, Tsukimori K et al (2005) Tumor necrosis factor and vascular endothelial growth factor induce endothelial integrin repertories, regulating endovascular differentiation and apoptosis in a human extravillous trophoblast cell line. Biol Reprod 73:172–179PubMedCrossRef Fukushima K, Miyamoto S, Tsukimori K et al (2005) Tumor necrosis factor and vascular endothelial growth factor induce endothelial integrin repertories, regulating endovascular differentiation and apoptosis in a human extravillous trophoblast cell line. Biol Reprod 73:172–179PubMedCrossRef
8.
go back to reference Kupferminc M, Peaceman A, Aderka D (1995) Soluble tumor necrosis factor receptors in maternal plasma and second-trimester amniotic fluid. Am J Obstet Gynecol 173:900–905PubMedCrossRef Kupferminc M, Peaceman A, Aderka D (1995) Soluble tumor necrosis factor receptors in maternal plasma and second-trimester amniotic fluid. Am J Obstet Gynecol 173:900–905PubMedCrossRef
9.
go back to reference Ellis J, Wennerholm UB, Bengtsson A et al (2000) Levels of dimethylarginines and cytokines in mild and severe preeclampsia. Hum Reprod 80:602–608 Ellis J, Wennerholm UB, Bengtsson A et al (2000) Levels of dimethylarginines and cytokines in mild and severe preeclampsia. Hum Reprod 80:602–608
10.
go back to reference Bahar A, Ghalib H, Moosa R et al (2003) Maternal serum interleukin-6, interleukin-8, tumor necrosis factor-α and interferon-γ in preterm labor. Acta Obstet Gynecol Scand 82:543–549PubMedCrossRef Bahar A, Ghalib H, Moosa R et al (2003) Maternal serum interleukin-6, interleukin-8, tumor necrosis factor-α and interferon-γ in preterm labor. Acta Obstet Gynecol Scand 82:543–549PubMedCrossRef
11.
go back to reference Gerli R, Lunardi C, Vinante F et al (2001) Role of CD30+ T cells in rheumatoid arthritis: a counter-regulatory paradigm for Th1-driven diseases. Trends Immunol 2:72–77CrossRef Gerli R, Lunardi C, Vinante F et al (2001) Role of CD30+ T cells in rheumatoid arthritis: a counter-regulatory paradigm for Th1-driven diseases. Trends Immunol 2:72–77CrossRef
12.
go back to reference Correale J, Arias M, Gilmore W (1998) Steroid hormone regulation of cytokine secretion by proteolipid protein-specific CD4+ T cells clone isolated from multiple sclerosis patients and normal control subjects. J Immunol 161:3365–3374PubMed Correale J, Arias M, Gilmore W (1998) Steroid hormone regulation of cytokine secretion by proteolipid protein-specific CD4+ T cells clone isolated from multiple sclerosis patients and normal control subjects. J Immunol 161:3365–3374PubMed
13.
go back to reference Chrousos G, Torpy D, Gold P (1998) Interactions between the hypothalamic–pituitary–adrenal axis and the female reproductive system: clinical implications. Ann Intern Med 129:229–240PubMed Chrousos G, Torpy D, Gold P (1998) Interactions between the hypothalamic–pituitary–adrenal axis and the female reproductive system: clinical implications. Ann Intern Med 129:229–240PubMed
14.
go back to reference Barrett J, Brennan P, Fiddler M et al (2000) Breastfeeding and postpartum relapse in women with rheumatoid and inflammatory arthritis. Arthritis Rheum 43:1010–1015PubMedCrossRef Barrett J, Brennan P, Fiddler M et al (2000) Breastfeeding and postpartum relapse in women with rheumatoid and inflammatory arthritis. Arthritis Rheum 43:1010–1015PubMedCrossRef
15.
go back to reference Somerset D, Zheng Y, Kilby M et al (2004) Normal human pregnancy is associated with an elevation in the immune suppressive CD4+CD25+ regulatory T cell subset. Immunology 112:38–43PubMedCrossRef Somerset D, Zheng Y, Kilby M et al (2004) Normal human pregnancy is associated with an elevation in the immune suppressive CD4+CD25+ regulatory T cell subset. Immunology 112:38–43PubMedCrossRef
16.
go back to reference Brennan P (1997) HLA sharing and history of miscarriage among women with rheumatoid arthritis. Am J Hum Genet 60:738–739PubMed Brennan P (1997) HLA sharing and history of miscarriage among women with rheumatoid arthritis. Am J Hum Genet 60:738–739PubMed
18.
go back to reference Crocker I, Baker P, Fletcher J (2000) Neutrophil function in pregnancy and rheumatoid arthritis. Ann Rheum Dis 59:555–564PubMedCrossRef Crocker I, Baker P, Fletcher J (2000) Neutrophil function in pregnancy and rheumatoid arthritis. Ann Rheum Dis 59:555–564PubMedCrossRef
19.
go back to reference Ostensen M (2004) New insights into sexual functioning and fertility in rheumatic diseases. Best Pract Res Clin Rheumatol 18(2):219–232PubMedCrossRef Ostensen M (2004) New insights into sexual functioning and fertility in rheumatic diseases. Best Pract Res Clin Rheumatol 18(2):219–232PubMedCrossRef
20.
go back to reference Perselin R (1977) The effect of pregnancy on rheumatoid arthritis. Bull Rheum Dis 27:922 Perselin R (1977) The effect of pregnancy on rheumatoid arthritis. Bull Rheum Dis 27:922
21.
go back to reference Silman A, Kay A, Brennan P (1992) Timing of pregnancy in relation to the onset of rheumatoid arthritis. Arthritis Rheum 35:152PubMedCrossRef Silman A, Kay A, Brennan P (1992) Timing of pregnancy in relation to the onset of rheumatoid arthritis. Arthritis Rheum 35:152PubMedCrossRef
22.
go back to reference Ostensen M, Husby G, Romberg O (1982) Ankylosing spondylitis and motherhood. Arthritis Rheum 25:140–143PubMedCrossRef Ostensen M, Husby G, Romberg O (1982) Ankylosing spondylitis and motherhood. Arthritis Rheum 25:140–143PubMedCrossRef
23.
go back to reference Skomsvoll J, Ostensen M, Schei B (2000) Reproduction in women reporting chronic musculoskeletal disorders. Scand J Rheumatol 29:103–107PubMedCrossRef Skomsvoll J, Ostensen M, Schei B (2000) Reproduction in women reporting chronic musculoskeletal disorders. Scand J Rheumatol 29:103–107PubMedCrossRef
24.
go back to reference Ostensen M, Ostensen H (1998) Ankylosing spondylitis—the female aspect. J Rheumatol 25:120–124PubMed Ostensen M, Ostensen H (1998) Ankylosing spondylitis—the female aspect. J Rheumatol 25:120–124PubMed
25.
go back to reference Khamashta M, Hughes G (1996) Pregnancy in systemic lupus erythematosus. Curr Opin Rheumatol 8:424–442PubMedCrossRef Khamashta M, Hughes G (1996) Pregnancy in systemic lupus erythematosus. Curr Opin Rheumatol 8:424–442PubMedCrossRef
26.
go back to reference Hardy C, Palmer BP, Morton S et al (1999) Pregnancy outcome and family size in systemic lupus erythematosus: a case-control study. Rheumatology 38:559–563PubMedCrossRef Hardy C, Palmer BP, Morton S et al (1999) Pregnancy outcome and family size in systemic lupus erythematosus: a case-control study. Rheumatology 38:559–563PubMedCrossRef
27.
go back to reference Clowse M, Madger L, Witter F et al (2006) Early risk factor for pregnancy loss in lupus. Obstet Gynecol 107:293–299PubMed Clowse M, Madger L, Witter F et al (2006) Early risk factor for pregnancy loss in lupus. Obstet Gynecol 107:293–299PubMed
28.
go back to reference Ruiz-Irastorza G, Lima F, Alves J et al (1996) Increased rate of lupus flare during pregnancy and the puerperium; a prospective study of 78 pregnancies. Br J Rheumatol 35:133PubMedCrossRef Ruiz-Irastorza G, Lima F, Alves J et al (1996) Increased rate of lupus flare during pregnancy and the puerperium; a prospective study of 78 pregnancies. Br J Rheumatol 35:133PubMedCrossRef
29.
go back to reference Kong N (2006) Pregnancy of a lupus patient—a challenge to the nephrologist. Nephrol Dial Transplant 21:268PubMedCrossRef Kong N (2006) Pregnancy of a lupus patient—a challenge to the nephrologist. Nephrol Dial Transplant 21:268PubMedCrossRef
31.
go back to reference McNeil H, Chesterman C, Krilis S (1991) Immunology and clinical importance of antiphospholipid antibodies. Adv Immunol 49:193PubMedCrossRef McNeil H, Chesterman C, Krilis S (1991) Immunology and clinical importance of antiphospholipid antibodies. Adv Immunol 49:193PubMedCrossRef
32.
go back to reference Gordon P, Khamasthta M, Rosenthal E et al (2004) Anti-52 kDa Ro, anti-60 kDa Ro and anti-La antibody profiles in neonatal lupus. J Rheumatol 31:2480–2487PubMed Gordon P, Khamasthta M, Rosenthal E et al (2004) Anti-52 kDa Ro, anti-60 kDa Ro and anti-La antibody profiles in neonatal lupus. J Rheumatol 31:2480–2487PubMed
33.
go back to reference Tsakonas E, Esdaile J, Choquette D et al (1998) A long-term study on hydroxychloroquine withdrawal on exacerbations of systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. Lupus 7(2):80–85PubMedCrossRef Tsakonas E, Esdaile J, Choquette D et al (1998) A long-term study on hydroxychloroquine withdrawal on exacerbations of systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. Lupus 7(2):80–85PubMedCrossRef
34.
go back to reference Steen V, Conte C, Day N et al (1989) Pregnancy in women with systemic sclerosis. Arthritis Rheum 32:151–157PubMedCrossRef Steen V, Conte C, Day N et al (1989) Pregnancy in women with systemic sclerosis. Arthritis Rheum 32:151–157PubMedCrossRef
35.
go back to reference Black C, Stevens W (1989) Scleroderma. Rheum Dis Clin North Am 15:193PubMed Black C, Stevens W (1989) Scleroderma. Rheum Dis Clin North Am 15:193PubMed
36.
go back to reference Scialli A, Buelke-Sam J, Chambers C et al (2004) Communicating risks during pregnancy: a workshop on the use of data from animal developmental toxicity studies in pregnancy labels for drugs. Birth Defects Res A Clin Mol Teratol 70:7–12PubMedCrossRef Scialli A, Buelke-Sam J, Chambers C et al (2004) Communicating risks during pregnancy: a workshop on the use of data from animal developmental toxicity studies in pregnancy labels for drugs. Birth Defects Res A Clin Mol Teratol 70:7–12PubMedCrossRef
37.
go back to reference Park-Wyllie L, Mazzotta P, Pastuszak A et al (2000) Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 62:385–392PubMedCrossRef Park-Wyllie L, Mazzotta P, Pastuszak A et al (2000) Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 62:385–392PubMedCrossRef
38.
go back to reference Blanford A, Murphy B (1977) In vitro metabolism of prednisolone, dexamethasone, betamethasone, and cortisol by the human placenta. Am J Obstet Gynecol 127:264–267PubMed Blanford A, Murphy B (1977) In vitro metabolism of prednisolone, dexamethasone, betamethasone, and cortisol by the human placenta. Am J Obstet Gynecol 127:264–267PubMed
39.
go back to reference Temprano K, Bandlamudi R, Moore T (2005) Antirheumatic drugs in pregnancy and lactation. Semin Arthritis Rheum 35:112–121PubMedCrossRef Temprano K, Bandlamudi R, Moore T (2005) Antirheumatic drugs in pregnancy and lactation. Semin Arthritis Rheum 35:112–121PubMedCrossRef
40.
42.
go back to reference Canadian Rheumatology Association (2000) Canadian Consensus Conference on Hydroxychloroquine. J Rheumatol 27:2919–2920 Canadian Rheumatology Association (2000) Canadian Consensus Conference on Hydroxychloroquine. J Rheumatol 27:2919–2920
43.
go back to reference Costedoat-Chalumeau N, Amoura Z, Dunaut P et al (2003) Safety of hydroxychloroquine in pregnant patients with connective tissue disease. Arthritis Rheum 48:3207–3214PubMedCrossRef Costedoat-Chalumeau N, Amoura Z, Dunaut P et al (2003) Safety of hydroxychloroquine in pregnant patients with connective tissue disease. Arthritis Rheum 48:3207–3214PubMedCrossRef
44.
go back to reference Chambers C, Tutuncu Z, Johnson D et al (2006) Human pregnancy safety for agents used to treat rheumatoid arthritis: adequacy of available information and strategies for developing post-marketing data. Arthritis Res Ther 8:215PubMedCrossRef Chambers C, Tutuncu Z, Johnson D et al (2006) Human pregnancy safety for agents used to treat rheumatoid arthritis: adequacy of available information and strategies for developing post-marketing data. Arthritis Res Ther 8:215PubMedCrossRef
45.
go back to reference Jarnerot G, Into-Malmberg M (1979) Sulphasalazine treatment during breastfeeding. Scand J Gastroentrol 14:869–871CrossRef Jarnerot G, Into-Malmberg M (1979) Sulphasalazine treatment during breastfeeding. Scand J Gastroentrol 14:869–871CrossRef
46.
go back to reference Committee on Drugs (1994) American academy of pediatrics: the transfer of drugs and other chemicals into human milk. Pediatrics 93:137–150 Committee on Drugs (1994) American academy of pediatrics: the transfer of drugs and other chemicals into human milk. Pediatrics 93:137–150
47.
go back to reference Armenti V, Ahlswede K, Ahlswede B et al (1994) National transplantation pregnancy registry-outcome of 154 pregnancies in cyclosporine-treated female kidney transplant recipients. Transplantation 57:502PubMedCrossRef Armenti V, Ahlswede K, Ahlswede B et al (1994) National transplantation pregnancy registry-outcome of 154 pregnancies in cyclosporine-treated female kidney transplant recipients. Transplantation 57:502PubMedCrossRef
48.
go back to reference Armenti V, Radomski J, Moritz M et al (2001) Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation. In: Terasaki P, Cecka JM (eds) Clinical transplants. UCLA Immunogenetics Center, Los Angeles, pp 97–105 Armenti V, Radomski J, Moritz M et al (2001) Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation. In: Terasaki P, Cecka JM (eds) Clinical transplants. UCLA Immunogenetics Center, Los Angeles, pp 97–105
49.
go back to reference Katz J, Keenan G, Snith D (2003) Outcome of pregnancy in patients receiving infliximab for the treatment of Crohn’s disease and rheumatoid arthritis. Digestive Disease Week May 17–22, 2004 Orlando, FL Katz J, Keenan G, Snith D (2003) Outcome of pregnancy in patients receiving infliximab for the treatment of Crohn’s disease and rheumatoid arthritis. Digestive Disease Week May 17–22, 2004 Orlando, FL
50.
go back to reference Ostensen M, Eigenmann G (2004) Etanercept in breast milk. J Rheumatol 31:1017–1018PubMed Ostensen M, Eigenmann G (2004) Etanercept in breast milk. J Rheumatol 31:1017–1018PubMed
51.
go back to reference Kimby E, Sverrisdottir A, Elinder G (2004) Safety of rituximab therapy during the first trimester of pregnancy: a case history. Eur J Haematol 72:292–295PubMedCrossRef Kimby E, Sverrisdottir A, Elinder G (2004) Safety of rituximab therapy during the first trimester of pregnancy: a case history. Eur J Haematol 72:292–295PubMedCrossRef
52.
go back to reference Herold M, Schnohr S, Bittrich H (2001) Efficacy and safety of a combined rituximab chemotherapy during pregnancy. J Clin Oncol 19:3439PubMed Herold M, Schnohr S, Bittrich H (2001) Efficacy and safety of a combined rituximab chemotherapy during pregnancy. J Clin Oncol 19:3439PubMed
Metadata
Title
Pregnancy and rheumatic disease: “by the book” or “by the doc”
Authors
Stephanie O. Keeling
Anna E. Oswald
Publication date
01-01-2009
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 1/2009
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-008-1031-9

Other articles of this Issue 1/2009

Clinical Rheumatology 1/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.